BioNTech’s Board Shake-Up and €500 Million Savings Plan Signal a High-Stakes Bet on Cancer

BioNTech's 92% shareholder vote backs oncology shift; stock near 52-week low as market awaits pivotal Phase 3 data from Pumitamig and Gotistobart by 2026.

BioNTech’s shareholders have given the green light to a sweeping transformation that will see the company trade its pandemic-era identity for one built around oncology. At the annual meeting on 15 May, 92% of votes backed the strategic overhaul – a level of support that buys management time but does little to shield the stock from mounting scepticism. The shares closed at €76.95 on Friday, shedding 2.2% on the day and trading roughly 8% lower over the past month. With the 52-week low of €72.50 within striking distance and the stock more than 11% below its 200-day moving average, the market is clearly waiting for results before repricing the business.

The boardroom has been reinforced to match the new ambition. The supervisory board expanded from six to eight members, with the election of Prof. Iris Löw-Friedrich and Dr Susanne Schaffert, both of whom bring deep expertise in global clinical development and commercialisation of oncology drugs. Helmut Jeggle took over as chairman, while Anja Morawietz and Rudolf Staudigl had their mandates extended. The appointments underscore a leadership determined to shed the pure-play vaccine label.

That determination comes at a price. BioNTech confirmed its 2026 revenue guidance of between €2.0 billion and €2.3 billion, a range that reflects the continued decline in COVID-19 product sales. But spending remains heavy: research and development costs are budgeted at up to €2.5 billion, and administrative expenses could reach €800 million. To offset the burn, management has unveiled a cost-reduction programme targeting roughly €500 million in annual savings by 2029, largely through consolidation of the manufacturing network. A $3.5 billion upfront payment from the partnership with Bristol Myers Squibb is providing near-term relief, while a $1 billion American depositary share buyback programme, authorised through May 2027, is intended to signal confidence.

The company’s financial cushion is formidable: liquid assets and securities stood at nearly €16.8 billion at the end of the first quarter. That war chest is being deployed into an extensive clinical pipeline that currently features 15 active Phase 3 trials. The two programmes drawing the most attention are the pan-tumour candidate Pumitamig (BNT327) and the CTLA-4 antibody Gotistobart. Both are being developed alongside Bristol Myers Squibb, and five pivotal studies for Pumitamig alone are under way.

The first major data readouts are not expected until the second half of 2026. BioNTech has flagged six late-stage clinical data packages for delivery that year, and analysts are watching closely. The average price target among sell-side analysts stands at $131.60, with a consensus rating of “Moderate Buy”. Whether that optimism is warranted will depend entirely on whether the pipeline can translate a strategic vision into clinical reality – and whether the market is willing to wait until 2026 to find out.